BACKGROUND: This study was designed to prospectively evaluate the role of nebulized hyaluronic acid (HA) given for 10 days/mo over 3 months as adjunct treatment to minimize symptoms and preventing exacerbation of chronic rhinosinusitis (CRS). METHODS:Thirty-nine eligible patients were randomized to receive nebulized 9-mg sodium hyaluronate nasal washes plus saline solution (21 patients) or 5 mL of saline alone (18 patients), according to an open-label, parallel-group design, with blind observer assessment. A questionnaire about main CRS discomfort and nasal endoscopy for mucous discharge and/or mucosal edema of nasal cavities was used to assess primary outcomes of treatments. Secondary outcome measures included side effects and satisfaction. RESULTS: HA significantly improved quality of life in CRS patients according to the CRS questionnaire (16± 3.72 versus 11.52 ± 4.28; p < 0.001), contrary to saline group scores (18.92 ± 3.09 versus 18.21 ± 3.21; p = 0.55). The HA group showed significantly reduced osteomeatal edema (2.42 versus 1.52; p < 0.001) and secretions (0.95 versus 0.42; p < 0.001), whereas there was no statistically significant difference in the saline group. The compliance to the treatment was similar in both groups and no side effects were recorded. CONCLUSION: The results of this study suggested that intermittent treatment with topical 9-mg sodium hyaluronate plays a role in minimizing symptoms and could prevent exacerbations of CRS.
RCT Entities:
BACKGROUND: This study was designed to prospectively evaluate the role of nebulized hyaluronic acid (HA) given for 10 days/mo over 3 months as adjunct treatment to minimize symptoms and preventing exacerbation of chronic rhinosinusitis (CRS). METHODS: Thirty-nine eligible patients were randomized to receive nebulized 9-mg sodium hyaluronate nasal washes plus saline solution (21 patients) or 5 mL of saline alone (18 patients), according to an open-label, parallel-group design, with blind observer assessment. A questionnaire about main CRS discomfort and nasal endoscopy for mucous discharge and/or mucosal edema of nasal cavities was used to assess primary outcomes of treatments. Secondary outcome measures included side effects and satisfaction. RESULTS:HA significantly improved quality of life in CRSpatients according to the CRS questionnaire (16± 3.72 versus 11.52 ± 4.28; p < 0.001), contrary to saline group scores (18.92 ± 3.09 versus 18.21 ± 3.21; p = 0.55). The HA group showed significantly reduced osteomeatal edema (2.42 versus 1.52; p < 0.001) and secretions (0.95 versus 0.42; p < 0.001), whereas there was no statistically significant difference in the saline group. The compliance to the treatment was similar in both groups and no side effects were recorded. CONCLUSION: The results of this study suggested that intermittent treatment with topical 9-mg sodium hyaluronate plays a role in minimizing symptoms and could prevent exacerbations of CRS.
Authors: Christopher Kuehl; Ti Zhang; Lisa M Kaminskas; Christopher J H Porter; Neal M Davies; Laird Forrest; Cory Berkland Journal: Mol Pharm Date: 2016-05-24 Impact factor: 4.939
Authors: J R Kuiper; A G Hirsch; K Bandeen-Roche; A S Sundaresan; B K Tan; R P Schleimer; R C Kern; W F Stewart; B S Schwartz Journal: Allergy Date: 2018-02-07 Impact factor: 13.146
Authors: Collin G Johnson; Vandy P Stober; Jaime M Cyphert-Daly; Carol S Trempus; Gordon P Flake; Valbona Cali; Israr Ahmad; Ronald J Midura; Mark A Aronica; Sadis Matalon; Stavros Garantziotis Journal: Am J Physiol Lung Cell Mol Physiol Date: 2018-09-06 Impact factor: 5.464
Authors: Manuele Casale; Antonio Moffa; Lorenzo Sabatino; Annalisa Pace; Giuseppe Oliveto; Massimiliano Vitali; Peter Baptista; Fabrizio Salvinelli Journal: PLoS One Date: 2015-06-29 Impact factor: 3.240
Authors: Do-Yang Park; Ji Ho Choi; Dong-Kyu Kim; Yong Gi Jung; Sue Jean Mun; Hyun Jin Min; Soo Kyoung Park; Jae-Min Shin; Hyung Chae Yang; Seung-No Hong; Ji-Hun Mo Journal: Clin Exp Otorhinolaryngol Date: 2022-02-15 Impact factor: 3.372